At the time of writing, Lexaria Bioscience Corp [LEXX] stock is trading at $1.02, up 3.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LEXX shares have gain 9.84% over the last week, with a monthly amount glided 14.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of Lexaria Bioscience Corp fluctuated between $0.77 and $2.85. Lexaria Bioscience Corp [NASDAQ: LEXX] shares were valued at $1.02 at the most recent close of the market.
Analyzing the LEXX fundamentals
According to Lexaria Bioscience Corp [NASDAQ:LEXX], the company’s sales were 0.62M for trailing twelve months, which represents an 107.14% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -18.5%, Pretax Profit Margin comes in at -18.5%, and Net Profit Margin reading is -18.49%. To continue investigating profitability, this company’s Return on Assets is posted at -1.69, Equity is -1.49 and Total Capital is -2.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9677 points at the first support level, and at 0.9155 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0561, and for the 2nd resistance point, it is at 1.0923.
Ratios To Look Out For
It is important to note that Lexaria Bioscience Corp [NASDAQ:LEXX] has a current ratio of 3.90. As well, the Quick Ratio is 3.90, while the Cash Ratio is 3.09. Considering the valuation of this stock, the price to sales ratio is 36.56, the price to book ratio is 3.57.
Transactions by insiders
Recent insider trading involved BUNKA CHRISTOPHER, Director, that happened on Jul 29 ’25 when 15600.0 shares were purchased. Director, BUNKA CHRISTOPHER completed a deal on Jul 30 ’25 to buy 11900.0 shares. Meanwhile, Director McKechnie William Edward bought 5000.0 shares on Jul 29 ’25.
